AddLife AB (ALIF-B) Fair Value & Analysis
Healthcare · SE · Market cap 20.2B SEK
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 5 days ago
Share price +0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 133.22 – kr 204.67 · fair‑value band kr 60.87 – kr 107.54 · the kr 157.00 price screens above the kr 81.17 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AddLife AB (ALIF-B) currently trades at kr 157.00, while our model-based Fair Value estimate is kr 81.17, implying the stock looks roughly 48.3% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, AddLife AB generated revenue of 10.4B SEK at a net margin of 5.5%. Revenue declined 2.1% year over year. It earns a return on equity of 10.6%. Net debt stands at 4.0B SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 60.87 (bear case) to kr 107.54 (bull case); at kr 157.00, the current price sits above that range. The share trades about 24% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -48%, ALIF-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry. This segment also provides training programs for its customers. The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AddLife AB reported revenue of kr 10.4B in FY2025 versus kr 8.0B in FY2021, a compound +6.9%/yr. Reported net income was kr 560M in FY2025, compounding −6.1%/yr from FY2021.
Is ALIF-B fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$9.25 | -56% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $67.81 | $39.78 | -41% |
| ResMed Inc RMD | $196.04 | $185.14 | -6% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $12.68 | $5.49 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AddLife AB (ALIF-B) undervalued?
What is the fair value of ALIF-B?
What is the quality score of ALIF-B?
What is the revenue of AddLife AB (ALIF-B)?
What is the net profit margin of ALIF-B?
Does AddLife AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full AddLife AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.